Hiroshi Miyamoto, MD, PhD, currently serving as the Director of Genitourinary Pathology at the University of Rochester Medical Center, Rochester, New York, USA, is trained and has worked both as a urologist (in Japan) and as a pathologist (in the USA). He has also been engaged in research mainly involving bladder and prostate cancers. His primary research interest is the molecular biology of steroid hormone receptors in genitourinary tumors. Specifically, he has been investigating the role of androgen receptor signaling in promoting the development and progression of bladder cancer, as well as resistance to conventional non-surgical therapy. Additionally, as a surgical pathologist, he has been assessing the histopathological and immunohistochemical features of genitourinary cancers, primarily to improve their risk stratification.